Sugi Predict

Sugi Predict / Compounds / SCHEMBL932313

SCHEMBL932313

SCHEMBL932313

Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OP(O)(O)=S)[C@@H](O)[C@H]2O)c(=O)[nH]1

nearest known ligand 0.80

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ TGM2 P21980 1/20 0.80
▸ NT5E P21589 1/20 0.75
▸ KRAS P01116 5/20 0.75
▸ FUT5 Q11128 1/20 0.74
▸ P2RX3 P56373 2/20 0.70
▸ P2RY1 P47900 4/20 0.68
▸ P2RY11 Q96G91 1/20 0.68
▸ P2RY2 P41231 3/20 0.68
▸ P2RY4 P51582 1/20 0.68
▸ P2RY6 Q15077 1/20 0.68
▸ DCPS Q96C86 1/20 0.64
▸ SRC P12931 1/20 0.63
▸ P2RX1 P51575 1/20 0.63
▸ P2RX4 Q99571 1/20 0.63
▸ P2RX2 Q9UBL9 1/20 0.63
▸ ALDH1A1 P00352 1/20 0.63
▸ SMN1; SMN2 Q16637 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2706655 1.00 TGM2 (0.80) TGM2NT5EKRASFUT5P2RX3
SCHEMBL29399391 1.00 TGM2 (0.80) TGM2NT5EKRASFUT5P2RX3
SCHEMBL20277520 1.00 TGM2 (0.80) TGM2NT5EKRASFUT5P2RX3
SCHEMBL20282956 1.00 TGM2 (0.80) TGM2NT5EKRASFUT5P2RX3
SCHEMBL20277656 1.00 TGM2 (0.80) TGM2NT5EKRASFUT5P2RX3
SCHEMBL29429843 0.96 TGM2 (0.85) TGM2NT5EKRASFUT5P2RX3
SCHEMBL851357 0.96 TGM2 (0.85) TGM2NT5EKRASFUT5P2RX3
SCHEMBL21067722 0.96 TGM2 (0.85) TGM2NT5EKRASFUT5P2RX3
SCHEMBL18769114 0.96 TGM2 (0.85) TGM2NT5EKRASFUT5P2RX3
Gtp SCHEMBL17367368 0.94 TGM2 (0.81) TGM2NT5EKRASFUT5P2RX3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 301 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024233640-A1 COMPOSITIONS AND METHODS FOR INHIBITING SEIZURES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-11-14 — — WO claimed
CN-114958901-B In-vitro preparation, activity detection and application of antifungal drug action target point 华中科技大学 2024-06-04 — — CN claimed
CN-116200410-A Glucan synthetase mutant with improved enzyme activity, preparation and drug screening application 华中科技大学 2023-06-02 — — CN claimed
CN-114958901-A In-vitro preparation, activity detection and application of antifungal drug action target 华中科技大学 2022-08-30 — — CN claimed
US-20120122787-A1 METHODS FOR TREATING POLYCYSTIC KIDNEY DISEASE (PKD) OR OTHER CYST FORMING DISEASES STOWERS INSTITUTE FOR MEDICAL RESEARCH 2012-05-17 — — US claimed
US-20110195433-A1 Methods for Screening of Opioid Receptor Neutral Antagonists and Inverse Agonists and Uses Thereof THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2011-08-11 — — US claimed
WO-2009079489-A1 METHODS FOR SCREENING OF OPIOID RECEPTOR NEUTRAL ANTAGONISTS AND INVERSE AGONISTS AND USES THEREOF THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2009-06-25 — — WO claimed
US-20260116914-A1 METHODS OF GENERATING NANOARRAYS AND MICROARRAYS NAUTILUS SUBSIDIARY INC (US) 2026-04-30 — — US disclosed
US-12522656-B2 Anti-G-protein alpha antibody CISBIO BIOASSAYS (FR) 2026-01-13 — — US disclosed
US-20250349136-A1 METHODS AND SYSTEMS FOR COMPUTATIONAL DECODING OF BIOLOGICAL, CHEMICAL, AND PHYSICAL ENTITIES NAUTILUS SUBSIDIARY INC (US) 2025-11-13 — — US disclosed
US-20250346611-A1 FLUORESCENT GTP ANALOGUES AND USE CISBIO BIOASSAYS (FR) 2025-11-13 — — US disclosed
US-12398158-B2 Fluorescent GTP analogues and use CISBIO BIOASSAYS (FR) 2025-08-26 — — US disclosed
US-12394223-B2 Methods and systems for computational decoding of biological, chemical, and physical entities NAUTILUS SUBSIDIARY, INC. (US) 2025-08-19 — — US disclosed
US-5430136-A Oligonucleotides having selectably cleavable and/or abasic sites CHIRON CORPORATION (US) 1995-07-04 — — US disclosed
WO-1995007983-A1 HUMAN MU OPIOID RECEPTOR INDIANA UNIVERSITY FOUNDATION (US) 1995-03-23 — — WO disclosed
WO-1995003819-A1 REGULATION OF OXIDATIVE BURST USING LMWG-DERIVED PEPTIDES AND ANALOGS THE SCRIPPS RESEARCH INSTITUTE (US) 1995-02-09 — — WO disclosed
US-5367066-A Oligonucleotides with selectably cleavable and/or abasic sites CHIRON CORPORATION (US) 1994-11-22 — — US disclosed
US-5294534-A Amplification method for polynucleotide assays MILES, INC. (US) 1994-03-15 — — US disclosed
US-5258506-A Photolabile reagents for incorporation into oligonucleotide chains CHIRON CORPORATION (US) 1993-11-02 — — US disclosed
EP-0530526-A1 Novel amplification method for polynucleotide assays Bayer Corporation (US) 1993-03-10 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250346611-A1 FLUORESCENT GTP ANALOGUES AND USE GNAI3, GNAQ, GNB1 TGM2 140/4885NT5E 344/4885KRAS 9/4885
US-12398158-B2 Fluorescent GTP analogues and use GNAI3, GNAQ, GNB1 TGM2 140/4885NT5E 344/4885KRAS 9/4885
US-20260116914-A1 METHODS OF GENERATING NANOARRAYS AND MICROARRAYS SPPL2B, SNAP29, SPPL2A TGM2 4113/4885NT5E 152/4885KRAS 3781/4885
US-20120122787-A1 METHODS FOR TREATING POLYCYSTIC KIDNEY DISEASE (PKD) OR OTHER CYST FORMING DISEASES PKD2, PKD1, HDAC4 TGM2 756/4885NT5E 3671/4885KRAS 441/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.